The drug-funding agency estimated that 1200 patients would benefit this year, rising to more than 5000 annually after 2030.

Upadacitinib demonstrated significant clinical and endoscopic remission in Crohn's disease patients, including those with prior advanced therapy exposure, without new safety signals. The study ...

They are venetoclax and azacitidine to treat acute myeloid leukaemia, ibrutinib for chronic lymphocytic leukaemia, and upadacitinib (brand name Rinvoq) to treat eczema, ulcerative colitis ...

A total of 209 patients received upadacitinib at a dose of 15 mg, 107 received upadacitinib at a dose of 7.5 mg, and 112 received placebo; 70% of the patients had new-onset giant-cell arteritis ...

The study was an open-label extension of two phase 3 studies. Response to upadacitinib was maintained, with responses of “similar magnitude” after switching from placebo. Upadacitinib sustains ...

RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval is supported by data from ...

1 SELECT-GCA (M16-852) is a Phase 3, multicenter, randomized, double-blind placebo-controlled study designed to evaluate the safety and efficacy of upadacitinib in 428 patients with GCA.

AbbVie’s attempts to diversify beyond Humira have been boosted as its investigational drug upadacitinib has been granted Priority Review by the FDA for moderate to severe rheumatoid arthritis (RA).

That drug is upadacitinib, already under review by the FDA in moderate to severe rheumatoid arthritis, with a decision due from the FDA in the coming months after the regulator granted a faster ...